To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for ophthalmic anti-Inflammatory treatments shows that under the pharmacy benefit, almost 64% and 42% of the lives under commercial formularies and Medicare formularies are covered without utilization management restrictions, respectively.
Trends: There are numerous products in the ophthalmic anti-inflammatory pipeline; many are new formulations or strengths of the same chemical entity, while only one is a new molecule. Via AIS Health.